Clinical Trial Update: L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Hypothyroxinemia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating L-thyroxine supplementation in preterm newborns (<32 weeks) with hypothyroxinemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypothyroxinemia in Preterm Newborns

Drugs mentioned

• L-Thyroxine (levothyroxine)

Snippet

Sponsor: Centre Hospitalier Universitaire, Amiens | Conditions: Hypothyroxinemia | Phase 3 | Status: COMPLETED